But Northeastern’s professor of pharmaceutical sciences and chemical engineering, Mansoor Amiji, was blunter, telling Newsweek: “Except for GLP-1 agonists by Eli Lilly and Novo, and other FDA-approved peptides, there are no preclinical or clinical studies showing safety and effectiveness of these ‘hyped’ peptides.”
